SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Immix Biopharma, Inc. operates as a biopharmaceutical company that engages in the development of therapies for cancer and inflammatory diseases. The company was founded by Ilya Rachman, Sean Senn, and Vladimir Torchilin in 2012 and is headquartered in Los Angeles, CA.

Immix Biopharma Inc

IMMX is trending due to promising clinical data for its CAR-T therapy NXC-201 in treating AL Amyloidosis, specifically a high complete response rate and organ-level improvements. The community is excited about the potential for NXC-201 to become a first-in-class FDA-approved treatment, especially given its orphan drug status and RMAT designation. Some are drawing comparisons to other recent CAR-T approvals and M&A activity in the biotech sector, suggesting a potential for IMMX to be an acquisition target.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as natural gas prices experience volatility, with some traders anticipating a downturn due to high production and storage levels despite colder weather forecasts. The community is actively discussing potential entry points, swing trading strategies, and the impact of weather patterns on natural gas demand. Concerns about an oversupply and a possible short squeeze are also prevalent, creating a mixed sentiment around KOLD's near-term direction.

Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.

Structure Therapeutics Inc - ADR

GPCR is trending as community members discuss the potential of its upcoming data and its competitive positioning against other obesity treatments. Community interest appears to be fueled by speculation about potential acquisitions, especially given the recent activity in the GLP-1 space. Some are also discussing the company's financial health and recent stock performance.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token is experiencing a surge, hitting price levels not seen since July 2025, with community members drawing comparisons to early DOGE and PEPE. The enthusiasm is fueled by the idea of a meme trifecta alongside DOGE and PEPE, and a narrative around Vitalik Buterin and the Ethereum ecosystem.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic ($LUNC) is trending amid community discussions about potential price movements and burning mechanisms to reduce token supply. Some investors express optimism based on possible catalysts abroad and the potential for significant gains, while others remain skeptical, citing past crashes and market manipulation.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

$KODK is trending after hitting a new 52-week high, fueled by positive Q3 earnings, a completed pension reversion poised to significantly reduce debt, and the potential for a pharmaceutical contract. Community members are closely watching for news related to their pharmaceutical and battery business ventures, with some speculating about government support and potential meme stock status. Bullish sentiment surrounds the company's turnaround and future growth prospects.

CryingNTheCasino

$TEARY is trending due to its 'No Crying In The Casino' narrative, with the community emphasizing its strong belief in the project and long-term potential. Discussions highlight the power of community-driven growth and the idea of holding strong during market volatility. Investors are expressing patience and anticipation for future developments.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

XYO Network is experiencing increased attention, with community members actively discussing recent price pumps and anticipating potential catalysts. Speculation around partnerships, particularly with Tesla, and the upcoming Layer 1 release are key talking points. Despite the enthusiasm, some traders express concerns about pump-and-dump patterns and question the project's long-term value.

Rayls is a Layer-1 blockchain ecosystem designed for financial institutions to bridge traditional finance (TradFi) and decentralized finance (DeFi). Developed by Parfin, Rayls combines a public chain, private networks, and institutional privacy nodes into a unified infrastructure that supports compliant, scalable, and privacy-preserving asset tokenization and settlement. Its architecture connects regulated banks and payment systems with public DeFi liquidity while maintaining confidentiality through the Rayls Enygma privacy protocol. The network enables tokenization of real-world assets, CBDCs, and stablecoins using EVM-compatible technology, fixed USD-pegged gas fees, deterministic finality, and harmful MEV protection.

Rayls

Rayls ($RLS) is trending as traders discuss its potential after a recent Coinbase listing, with some noting its initial spike and current low market cap as an opportunity for significant gains. The community is debating its potential for a pump, while also cautioning about potential risks and comparing it to other meme coins. Optimists highlight the project's fundamentals and potential catalysts, while others express concerns about its price action.

Direxion Shares ETF Trust - Direxion Daily TSLA Bull 2X Shares

Direxion Daily TSLA Bull 2X Shares

TSLL is trending due to optimism surrounding Tesla's potential breakout and upcoming delivery numbers, with many traders anticipating a move towards higher price targets. The community is actively discussing potential catalysts, including positive news and technical indicators, while weighing the risks associated with leveraged ETFs. Some are also noting a possible renewed relationship between Elon Musk and Trump.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<a href="https://stocktwits.com/symbol/DRREDDY.NSE">Shares of Dr. Reddy’s Laboratories</a> are on track to break through a critical range between ₹1,200 and ₹1,220 where surpassing resistance levels might lead to a significant price increase, according to SEBI-registered analyst Prameela Balakkala.<stembedurl>https://stocktwits.com/Prameela_Balakkala/message/614253319</stembedurl>The stock displays a strong technical and fundamental configuration following its fourth-quarter (Q4) earnings beat.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/DRREDDY.NSE">Dr. Reddy’s shares</a> were trading at ₹1,184.6, up 2.48% for the day.&nbsp;The company hit a 22% year-over-year net profit growth reaching ₹1,594 crore alongside a 20% revenue increase to ₹8,506 crore thanks to global product launches and new acquisitions including NRT.&nbsp;The company's EBITDA for the period reached ₹2,975 crore and its profit margins expanded to 29.1%.According to Balakkala, a breakout above ₹1,220 will establish ₹1,260 as the next target before potentially advancing toward ₹1,400 given continuous bullish momentum.&nbsp;The stock shows support levels at ₹1,100 and ₹1,060 on the downside.Despite existing risks from U.S. pricing pressures and macro factors, the stock should perform well based on current earnings and technical indicators, Balakkala said.On Stocktwits,&nbsp;retail sentiment was ‘bullish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/DRREDDY.NSE">Dr. Reddy’s shares</a> have declined 13.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Reddy’s Shares Eye Breakout As Q4 Beat Lifts Stock Toward ₹1,220 Resistance: SEBI RA Prameela Balakkala

Dr. Reddy’s shares are approaching a key resistance zone following a strong Q4FY25 earnings beat, according to Balakkala. A breakout above this level could trigger a rally toward ₹1,260 and ₹1,400.

Equity

Frame 485.png

Get the daily email that keeps you tuned in and makes markets fun again.

Frame 484.png

The most relevant Indian markets intel delivered to you everyday.

cryptotwits - 800x800.png

Get the daily crypto email you’ll actually love to read. It's value-packed, data-driven, and seasoned with wit.

Frame 479.png

The best trade ideas and analysis from the Stocktwits community. Delivered daily by 8 pm ET.

Frame 486.png

For serious investors with a serious sense of humor.

Frame 487.png

High Relative Strength, Low Social Following

Dr. Reddy’s Shares Eye Breakout As Q4 Beat Lifts Stock Toward ₹1,220 Resistance: SEBI RA Prameela Balakkala

Latest News